Filing Flows › Karyopharm Therapeutics (KPTI) › Product revenue
Karyopharm Therapeutics (KPTI) Product revenue by quarter
Karyopharm Therapeutics' Product revenue was $30.8M in Q2 2026 (second quarter 2026), +6% from Q1 2026. Over the last 7 quarters it ranged from $21.1M (Q1 2025) to $32.1M (Q4 2025).
| Quarter | Product revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $30.8M | +6% | +4% |
| Q1 2026 | $29.2M | -9% | +39% |
| Q4 2025 | $32.1M | +0.2% | +10% |
| Q3 2025 | $32.0M | +8% | — |
| Q2 2025 | $29.7M | +41% | — |
| Q1 2025 | $21.1M | -28% | — |
| Q4 2024 | $29.3M | — | — |
Q2 2026 at a glance
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Karyopharm Therapeutics' Product revenue?
Karyopharm Therapeutics' Product revenue was $30.8M in Q2 2026 (second quarter 2026), +6% from Q1 2026.
How has Karyopharm Therapeutics' Product revenue changed?
Over the last 7 quarters it ranged from $21.1M (Q1 2025) to $32.1M (Q4 2025).
Q2 2026 results → · How Karyopharm Therapeutics makes money →